title: Ca2+ channel inhibition by a new dihydropyridine derivative, S11568, and its enantiomers S12967 and S12968.
abstract: Biochemical and electrophysiological techniques were used to describe the Ca2+ channel blocking properties of a new dihydropyridine derivative, S11568 (+/-)- ([(amino-2-ethoxy)-2-ethoxy]methyl)-2-(dichloro-2',3'-phenyl)-4- ethoxy-carbonyl-3-methoxycarbonyl-5-methyl-6-dihydro-1,4-pyridine and its enantiomers S12967 ((+)-S11568) and S12968 ((-)-S11568). In binding studies, S11568 and S12968 displaced specifically bound [3H]PN 200-110 from cardiac and vascular smooth muscle preparations with potencies of 5.6-51 nM, respectively. S12967 was 6- to 18-fold less potent than S12968. A good correlation was found between the IC50 value for the inhibition of 45Ca2+ uptake by A7r5 aortic smooth muscle cells and binding data. Whole-cell patch clamp studies in both guinea-pig ventricular myocytes and A7r5 cells yielded similar results. At holding potential (VH) -50 mV, S12968 inhibited L-type Ca2+ current with an IC50 value near 70 nM, 2- to 3-fold more potently than S11568 and 30-fold more potently than S12967. With VH -100 mV, all three compounds were less potent, with IC50 values ranging from 500 nM to 3 microM. These results demonstrate conclusively that S12968 is the more active enantiomer. Furthermore, the pronounced voltage dependence of its actions in vitro suggests that in vivo it could exhibit good selectivity for vascular smooth muscle over cardiac muscle.
authors.affiliation: Fondax, Groupe de Recherche Servier, Puteaux, France.
authors.forename: J C
authors.initials: JC
authors.lastname: Randle
authors.forename: A
authors.initials: A
authors.lastname: Lombet
authors.forename: N
authors.initials: N
authors.lastname: Nagel
authors.forename: C
authors.initials: C
authors.lastname: Abraham
authors.forename: H
authors.initials: H
authors.lastname: Aptel
authors.forename: J L
authors.initials: JL
authors.lastname: Peglion
authors.forename: J F
authors.initials: JF
authors.lastname: Renaud
mesh_terms: D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / Q000494:pharmacology; D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002132:Calcium Radioisotopes; D002460:Cell Line; D004095:Dihydropyridines / Q000378:metabolism / Q000494:pharmacology*; D004594:Electrophysiology; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects*; D066298:In Vitro Techniques; D007293:Inosine Triphosphate / Q000378:metabolism; D017275:Isradipine; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D009206:Myocardium / Q000166:cytology / Q000378:metabolism; D010069:Oxadiazoles / Q000494:pharmacology; D051381:Rats; D012433:Ryanodine / Q000378:metabolism; D013237:Stereoisomerism
chemical_list: D002121:Calcium Channel Blockers; D002132:Calcium Radioisotopes; D004095:Dihydropyridines; D010069:Oxadiazoles; D007293:Inosine Triphosphate; C067838:S 11568; D012433:Ryanodine; D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; D017275:Isradipine